Cinryze Launch Plans Bear Hallmarks Of Successful Orphan Strategies

ViroPharma/Lev scored a regulatory success with FDA's approval of Cinryze (C1 esterase inhibitor) for prophylaxis of hereditary angioedema. Now the firm needs to concentrate on turning that into a commercial success - and with the launch plans recently laid out, the firm seems poised to do that